Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G5MT
|
||||
| Former ID |
DIB018462
|
||||
| Drug Name |
11-deoxy-PGE1
|
||||
| Synonyms |
11-deoxy-PGE1; 11-deoxyprostaglandin E1; doproston
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539225] | ||
| Formula |
C20H34O4
|
||||
| InChI |
InChI=1S/C20H34O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12,14,16-18,21H,2-11,13,15H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1
|
||||
| InChIKey |
DPNOTBLPQOITGU-LDDQNKHRSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [534595] | |
| Prostaglandin E2 receptor, EP4 subtype | Target Info | Agonist | [525852] | ||
| Prostaglandin E2receptor, EP2 subtype | Target Info | Agonist | [534478] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Regulation of lipolysis in adipocytes | |||||
| Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04024:cAMP signaling pathway | |||||
| Pathways in cancer | |||||
| References | |||||
| Ref 525852 | Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26. | ||||
| Ref 534478 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. | ||||
| Ref 534595 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.